premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly SLP is a $1.2 billion healthcare software company that provides modeling and simulation products to drug companies and biotechs and other sectors. Recently reported revenues were up 27% on the year and net income rose 49%. Their recurring revenue model helps produce 78% gross margins and it carries minimal long term debt. It pays a small dividend, backed by a 45% payout ratio. We would buy this with a stop loss at $40, looking to achieve $83 -- upside potential over 40%. Yield 0.38% (Analysts’ price target is $82.50)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly As consumers become more comfortable with online commerce, SHOP is well positioned to continue to see significant growth. It offers retailers an efficient way to sell directly and it collects recurring revenues through subscription fees. Earnings will be reported April 28 and the market expects EPS of $0.71 US and revenue of over $848 million US. Growth is expected to be modest compared to more than 1200% last year. Its success as a Canadian company has allowed it to build its cash position to over $2 billion US. We would buy this with a stop loss at $1000, looking to achieve $2000 -- upside potential over 30%. Yield 0% (Analysts’ price target is $2002.76)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly TLT is an ETF that represents US 20 long term treasury bonds of a term of 20+ years. Yields on these treasuries have been rising steadily since the pandemic based market collapse last March from under 1.00% to 2.25% now. This is a precautionary holding, to protect in the event of another market retracement. With the S&P500 trading at 22.4x earnings the market is at risk to correction if this season's reported earnings disappoint. As we consider this a hedge, we do not set a target or stop-loss, but instead will monitor trends in the underlying yield as a signal. Yield 1.61%
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 17/20, Up 93.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with APHA has triggered its stop at $19. To be disciplined, we recommend covering the position. Combined with the previous recommendation to cover 50%, this will create a net investment return of 59%.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 15/20, Up 36.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with HEXO has triggered its stop at $7.50. To be disciplined, we recommend covering the position. Combined with the previous recommendation to cover 50%, this will create a net investment return of 36%.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Feb 04/21, Down 19%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VFF has triggered its stop at $15.00. To be disciplined, we recommend covering the position. Combined with the previous recommendation to cover 50%, this will create a net investment return of 3.8%.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Oct 22/20, Up 19.6%)Stochchase Research Editor: Michael O'Reilly Our PAST TOP PICK with UNP has achieved its $225 target. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $160) to $206. This would all but guarantee a minimum investment return over 14%.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jan 28/21, Down 42.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with HYLN has triggered its stop at $10. To be disciplined, we recommend covering the position at this time. We will look for better opportunities.
COMMENT
Certain parts of the market are showing signs of a bubble. The causes are ease of access for the investing public and cheaper trading costs, which are both good and bad. He wants democratization of the market, but it's hard to succeed in the market and those entering the market with little or no knowledge could suffer losses. We're in a classic situation where the general public believes we're still in a recession when we exited that many months ago. This happened in 2009, too. Rather, markets are looking ahead with the U.S. going full bore as businesses expand. Earnings will hit new highs later this year. We'll likely grow 30% in earnings in 2021, while coming years look promising.
DON'T BUY
Their vaccine has been a boon to their revenues, which jumped 30% in a one year, but this is likely a round trip. Also, margins on this vaccine are fairly low. The vaccine offers some benefit to PFE, but it's limited. Look elsewhere.
DON'T BUY
This stalled a while ago. It trades at 26x earnings which is high. In the 1990s, this had a magical aura, when he owned it, but in those days Coke was growing. The pandemic has been very tough on Coke. Also, people are not drinking carbonated soft drinks as much.
BUY
It trades in line with peers at a reasonable 15x PE. Their cyber-defence division makes up a serious slice of its revenues. He likes this. The defence budget under Biden is still growing but not as quickly as before. That said, the defence industry will always see growth, but it's a matter of how fast or slow. Looking ahead, defence in general will focus on cyberattacks.
DON'T BUY

This morning the news said that distribution has been halted in the US, so the stock is declining today. Like Pfzier, JNJ is seeing a one-time bump because of their vaccine. JNJ is struggling in their consumer business as consumers move to generic drugs, not branded. Also, litigation remains a cloud, referring to asbestos in its Baby Powder. There are other opportunities in healthcare, like Anthem, the insurer, or retailer CVS, or Abbvie trading at a reasonable PE and offers good growth.

BUY
This will benefit if/when a US infrastructure plan really happens. Has a great balance sheet and is growing nicely, trading below 20x earnings. They recently bought a 5G infrastructure company, which is another plus.
BUY

It's a safe, solid choice, likely the best-run bank in the world under a superb CEO. There's still money to be made in the banks. JPM reports tomorrow. He wants to hear about their loan growth and net interest margins during this steeper yield curve. They've excelled in capital markets as SPACs continue to hum and he expects this to continue. They have many years of cost-cutting. BAC has slightly more upside, though.